Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats

Diabetes

Volumn 51, Issue 4, 2002, Pages 943-950

  Pospisilik, J A ^a   Stafford, S G ^a   Demuth, H U ^b   Brownsey, R ^a   Parkhouse, W ^c   Finegood, D T ^c   McIntosh, C H S ^a   Pederson, R A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROBIODRUG AG   (Germany)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DI 2 AMINO 3 METHYLPENTANOIC 1,3 THIAZOLIDINE FUMARATE; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; FUMARIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; ISOLEUCINE THIAZOLIDIDE; POLYPEPTIDE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HYPERINSULINEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LONG TERM CARE; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; RAT STRAIN; SOLEUS MUSCLE; TREATMENT OUTCOME;

EID: 0036228243     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.4.943     Document Type: Article

References (41)

1. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
2. Dipeptidyl-peptidase IV (CD26): Role in the inactivation of regulatory peptides
3. Metabolism of glucagon by dipeptidyl peptidase IV (CD26)
4. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas
5. N-terminal tyrosine-alanine is required for the insulin releasing activity of glucose-dependent insulinotropic polypeptide (GIP)
6. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-l-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry: A novel kinetic approach
7. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
8. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
9. Entero-insular axis
10. Gastric emptying and release of incretin hormones after glucose ingestion in humans
11. Inhibition of histamine-, pentagastrin-, and insulin-stimulated canine gastric secretion by pure "gastric inhibitory polypeptide"
12. Glucagon receptors on human islet cells contribute to glucose competence of insulin release
13. Insulinotropic hormone glucagon-like peptide-1(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells
14. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
15. Gastric inhibitory polypeptide
16. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells
17. Influence of glucagon-like peptide-1 on beta cell responsiveness
18. Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance
19. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
20. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
21. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats
22. Recent developments in inhibiting cysteine and serine proteases
23. Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas
24. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp
25. Evidence that insulin activates fat-cell acetyl-CoA carboxylase by increased phosphorylation at a specific site
26. A rapid filter paper assay for UDP-glucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose
27. Effect of jejunoileal bypass in the rat on the enteroinsular axis
28. Beta-cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death
29. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
30. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells
31. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells
32. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor
33. Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells
34. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus
35. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle
36. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
37. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs
38. One week continuous infusion of GLP-1 (7-37) improves glycemic control in NIDDM
39. Near normalisation of diurnal glucose concentrations by continuous administrations of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
40. Single dose treatment of diabetic patients by the inhibitor P32/98
41. Single dose-escalation study to investigate the safety and tolerability of the DP IV inhibitor P32/98 in healthy volunteers